CROIVALVE: Solution for Tricuspid Regurgitation Supports the Native Valve
Mary Stuart | June, 1 2018
Thanks to transcatheter aortic valve replacement (TAVR), many patients with heart valve disease have a new lease on life. That success is spilling over into mitral and tricuspid heart valve disease, which are both active areas of medical device innovation. Says Lucy O’Keeffe, CEO of Dublin-based start-up CroiValve, which is focusing on the repair of diseased tricuspid valves, “The
availability of a growing number of non-surgical treatments for the left side of the heart drives the need for non-surgical treatments on the right side.” O’Keeffe spoke to MedTech Strategist after CroiValve’s win at the MedTech Innovator Pitch Event & Stage Competition, at the MedTech Strategist Innovation Summit in Dublin, Ireland, in April 2018. From a pool of 45 companies preselected by a panel of judges consisting of investors, providers, and senior executives from medtech companies, CroiValve ultimately won the audience’s heart to take first place. Prize money allows the early-stage company to travel to MedTech Innovator’s showcase at the 2018 annual meeting of AdvaMed, the American trade association of the medical device industry.
